REal World Data in LYmphoma and Survival in Adults

Hospices Civils de Lyon6,000 enrolled

Overview

REALYSA cohort is a population-based epidemiological platform in real-life for lymphomas designed to enrich prognostic data, by integrating together epidemiological, clinical and biological data. REALYSA is a platform perfectly set up to * Study prognostic factors using integrated epidemiological and biological data (genetics), to better characterize the determinants of refractoriness and relapse in patients with lymphoma, to follow the growing number of survivors and describe median to long-term sequela, second cancer, quality of life (QoL)… * Document treatment effectiveness in real life and observance * Address socio-economical questions

Study Type

OBSERVATIONAL

Enrollment

6,000

Conditions

Diffuse Large B Lymphoma (DLBCL)Follicular Lymphoma (FL)Mantle Cell Lymphoma (MCL)Marginal Zone Lymphoma (MZL)T-cell Lymphoma (T-NHL)Hodgkin's Lymphoma (HL)

Interventions

Real-life epidemiological platform of lymphoma in FranceOTHER

The REALYSA database will be described with the following characteristics: * Number of patients included per month in total and according to subtype of lymphoma * Number of patients in each region in total and according to subtype of lymphoma

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Signature of the consent form for participation in the REALYSA cohort * Aged over 18 at the time of inclusion * Diagnosed with lymphoma in the last 6 months (180 days) * Lymphoma subtype belonging to at least one of the 7 histological subtypes: diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, T-cell lymphoma, Hodgkin's lymphoma, Burkitt lymphoma Exclusion Criteria: * Anti-lymphoma treatment already received (except pre-phase: typically corticosteroids, vincristine, cyclophosphamide, etoposide, alone or in combination) * Documented HIV infection * Any other lymphoma subtype not included in the list in Appendix 1. Of note, are excluded: * Chronic lymphocytic leukemia/small lymphocytic lymphoma * Hairy cell leukemia and variant * Lymphoplasmacytic lymphoma * Waldenström macroglobulinemia * Primary DLBCL of the central nervous system (CNS) * T-cell large granular lymphocytic leukemia * Chronic lymphoproliferative disorder of NK cells * Mycosis fungoides * Sézary syndrome * Primary cutaneous T cell lymphomas (mainly diagnosed and treated by dermatologists) * Post-transplant lymphoproliferative disorders (PTLD)

Locations (37)

Unité d'Hématologie Clinique, CH D'ARRAS

Arras, France

RECRUITING

Service d'Hématologie, CHU Jean Minjoz

Besançon, France

RECRUITING

Service d'Onco-radiolothérapie, Polyclinique Bordeaux Nord Aquitaine

Bordeaux, France

RECRUITING

Institut Bergonié

Bordeaux, France

Outcomes

Primary Outcomes

Progression-Free Survival (PFS)

Time frame: 5 years

Secondary Outcomes

Number of patients included per month in total and according to subtype of lymphoma

Time frame: 5 years

Number of patients in each region in total and according to subtype of lymphoma

Time frame: 9 years

Progression-Free Survival (PFS)

Time frame: 9 years

Event-Free Survival (EFS)

Time frame: 5 years

Event-Free Survival (EFS)

Time frame: 9 years

Overall Survival (OS)

Time frame: 5 years

Overall Survival (OS)

Time frame: 9 years

Net Survival

Time frame: 5 years

Net Survival

Time frame: 9 years

Response rate

Time frame: 5 years

Response rate

Time frame: 9 years

Duration of response

Time frame: 5 years

Duration of response

Time frame: 9 years

Time to Next Anti-Lymphoma Treatment (TTNLT)

Time frame: 5 years

Time to Next Anti-Lymphoma Treatment (TTNLT)

Time frame: 9 years

Duration of Survival after progression

Time frame: 5 years

Duration of Survival after progression

Time frame: 9 years

Frequency of Lymphoma transformations

Time frame: 5 years

Frequency of Lymphoma transformations

Time frame: 9 years

Frequency of Second cancers

Time frame: 5 years

Frequency of Second cancers

Time frame: 9 years

Frequency of other chronic disease

Time frame: 5 years

Frequency of other chronic disease

Time frame: 9 years

Number of exposure factors

Time frame: Baseline

Number of comorbidities

Time frame: Baseline

Central Contacts

Hervé Ghesquières, MD

CONTACT

04 78 86 43 40 herve.ghesquieres@chu-lyon.fr

Alain Monnereau, MD

CONTACT

05 56 33 33 33 A.Monnereau@bordeaux.unicancer.fr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Centre Hospitalier Pierre Oudot

Bourgoin, France

RECRUITING

Service d'Hématologie, Institut d'Hématologie de Basse Normandie

Caen, France

RECRUITING

METROPOLE SAVOIE - SITE CHAMBERY, place Lucien Biset,

Chambéry, France

RECRUITING

Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Estaing, CHU de Clermont-Ferrand

Clermont-Ferrand, France

RECRUITING

Unité Hémopathies Lymphoïdes, Hôpital Henri Mondor

Créteil, France

RECRUITING

CHU Francois MITTERRAND

Dijon, France

RECRUITING

...and 27 more locations